Actively Recruiting
Comparing Aescin-Based Herbal Extract Reparil and Ibuprofen for Managing Pain and Swelling After Impacted Mandibular Third Molar Surgery
Led by Oman Medical Speciality Board · Updated on 2026-01-15
100
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research investigates the effects of an Aescin-based herbal extract called Reparil compared with Ibuprofen in managing symptoms after surgical removal of impacted lower wisdom teeth. The study focuses on people aged 18 to 40 who undergo this common oral surgery, aiming to find out if the herbal treatment offers pain relief and reduces swelling and limited mouth opening with fewer side effects than traditional nonsteroidal anti-inflammatory drugs NSAIDs. Participants will be randomly assigned to receive either Reparil tablets containing 20 mg Aescin or 400 mg Ibuprofen tablets, each taken orally three times a day for five days after surgery. Both groups follow the same schedule, and a rescue pain medication is available if needed. Assessments will occur before surgery and on days 2 and 7 afterward to measure pain, facial swelling using 3D scanning, and mouth opening using a digital caliper. During the study, participants will have their pain levels, facial swelling, and jaw movement tracked at specific intervals. Researchers will record any adverse effects and analyze data to compare the treatments impacts. The total involvement includes the surgery and follow-up visits on days 2 and 7, helping to evaluate the herbal extract as a potential alternative to Ibuprofen for managing post-surgical symptoms.
CONDITIONS
Brief Title
Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients indicated for surgical removal of impacted mandibular third molars according to NICE guidelines
- Age between 18 and 40 years
- Impacted mandibular third molars with similar anatomical position and difficulty level as classified by Pell and Gregory and Pederson scoring
- Healthy individuals classified as ASA I-II with no significant systemic illness
- Willing to provide written informed consent and attend all follow-up visits on Day 2 and Day 7 post-surgery
You will not qualify if you...
- Recent use (within three weeks preoperatively) of anti-inflammatories, corticosteroids, or antibiotics
- Known allergies or hypersensitivity to Aescin, Ibuprofen, rescue medications, or local anesthetics
- Pregnant or lactating women
- Patients with contraindications to NSAIDs such as asthma, bleeding disorders, chronic kidney disease, active peptic ulcer, or cardiovascular disease
- Recent use of substances that may affect surgery or interact with study drugs, including contraceptives, alcohol, or tobacco
- Surgical time exceeding 30 minutes or cases with intraoperative complications requiring non-study medications
Research Team
S
Suhail H AlSamari, BDS, MFD
V
Vidya Shetty, BDS, MDS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here